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EFFICACY AND SAFETY OF TAPENTADOL EXTENDED
RELEASE VERSUS OXYCODONE CONTROLLED RELEASE
IN OPIOID-NAIVE AND OPIOID-EXPERIENCED PATIENTS
WITH CHRONIC PAIN ASSOCIATED WITH
OSTEOARTHRITIS OF THE KNEE
M. Etropolski1, B. Lange2, B. Kuperwasser1, K. Kelly1,
A. Okamoto1, A. Steup2, I. Van Hove3, H. Weber2, J. Häussler1
1Johnson & Johnson Pharmaceutical Res. & Dev., L.L.C., Raritan,
NJ; 2Res. & Dev., Grünenthal GmbH, Aachen, Germany;
3Johnson & Johnson Pharmaceutical Res. & Dev., Div. of Janssen
Pharmaceutica, N.V., Beerse, Belgium
Purpose: To characterize the differential efﬁcacy and safety of
tapentadol extended release (ER) by prior opioid experience in
patients with moderate to severe chronic osteoarthritis knee pain.
Methods: Patients were randomized to receive controlled, ad-
justable bid doses of tapentadol ER (100-250 mg), oxycodone HCl
controlled release (CR; 20-50 mg), or placebo during a 12-week
maintenance period preceded by a 3-week titration period. Pa-
tients were categorized by prior opioid use during the 3 months
before screening. Change from baseline in average pain intensity
was assessed (11-point numerical rating scale) for the overall
maintenance period. Last observation carried forward was used to
impute pain measurements that were missing after discontinuation
of treatment.
Results: Opioid-naive patients represented 67.6% of the intent-
to-treat population (n = 1,023). The least squares mean difference
(LSMD; standard error of the mean [SEM]) from baseline in aver-
age pain intensity over the maintenance period in the opioid-naive
groups was statistically superior to placebo with tapentadol ER
(-0.7 [0.21]; P=0.001) but not with oxycodone CR (-0.3 [0.21];
P=0.139). Results were similar in the opioid-experienced groups
(tapentadol ER vs placebo, LSMD [SEM] = -0.8 [0.32], P=0.014;
oxycodone CR vs placebo, LSMD [SEM] = -0.5 [0.32], P=0.101).
The rate of study discontinuation was lower in the tapentadol ER
group than in the oxycodone CR group for opioid-naive (placebo,
35.0%; tapentadol ER, 41.7%; oxycodone CR, 68.8%) and opioid-
experienced (placebo, 45.6%; tapentadol ER, 45.0%; oxycodone
CR, 55.6%) patients. Rates of discontinuation due to adverse
events (AEs) were as follows: for opioid-naive patients, placebo,
7.2%; tapentadol ER, 19.6%; oxycodone CR, 48.3%; for opioid-
experienced patients, placebo, 5.3%; tapentadol ER, 18.3%; oxy-
codone CR, 31.5%. The incidence of overall and gastrointestinal-
related treatment-emergent AEs were lower in the tapentadol ER
group than in the oxycodone CR group, regardless of prior opioid
experience (Table 1).
Conclusions: Tapentadol ER (100-250 mg bid) is an effective
analgesic treatment with better overall and gastrointestinal tolera-
bility than oxycodone CR (20-50 mg bid), regardless of prior opioid
experience.
Abstract 328 – Table 1. TEAEs by Prior Opioid Experience
Opioid-naive Opioid-experienced
Placebo Tapentadol ER Oxycodone CR Placebo Tapentadol ER Oxycodone CR
n=223 n=235 n=234 n=114 n=109 n=108
All TEAEs (%) 61.0 79.6 87.2 61.4 67.9 88.0
Gastrointestinal-related 25.6 47.7 67.5 27.2 33.0 66.7
Nervous system-related 24.2 43.4 50.0 26.3 33.0 43.5
Skin and subcutaneous tissue-related 3.1 13.6 22.2 4.4 16.5 17.6
Psychiatric-related 4.5 12.3 16.2 5.3 12.8 12.0
Musculoskeletal and connective tissue-related 17.9 9.8 9.4 16.7 11.9 13.0
TEAEs, treatment-emergent adverse events; ER, extended release; CR, controlled release.
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ACCEPTABILITY OF A NOVEL 7 DAY BIMONTHLY
PARTICIPANT DIARY IN A LONG-TERM CLINICAL TRIAL
AMONG PEOPLE WITH SYMPTOMATIC KNEE OA
M. Agaliotis, L. Nairn, M. Votrubec, M. Fransen
Faculty of Hlth.Sci., Univ. of Sydney, Lidcombe, Australia
Purpose: To evaluate the participant acceptability of a cost-
effective novel participant diary engineered to regularly capture
relevant clinical outcomes and health economic data during the
course of a long-term clinical trial.
Methods: A novel Participant Diary was developed for participants
of a two year clinical trial evaluating the beneﬁts of glucosamine,
with or without chondroitin, in people with symptomatic knee
osteoarthritis (OA). The Participant Diary was dispatched with
the study treatment capsules every two months. The seven day
diary required the daily recording of knee pain ‘at its worst’
(rated 0-10), overall global assessment of arthritis (excellent to
poor; 0-4), participation in at least moderate physical activity for
more than 20 minutes (yes/no), use of analgesia (name; daily
S176 Poster Presentations
dosage) and presenteeism (work capacity; 0-100%). Participants
were also asked to report occasions of absenteeism and use of
health care services in the past two months. The methods used
before and during the trial to encourage correct completion and
timely return included: restriction of the diary to one colourful
page, piloting among patient and non-patient groups during the
development process, provision of a study magnet for attachment
to a kitchen appliance, feedback on diary completion during the
pre-randomisation run-in, and verbal encouragement during the
bimonthly participant retention telephone calls. Acceptability of
this novel measurement tool was evaluated by return of a correctly
completed Participant Diary within one month of despatch.
Results: At the end of 2008, 317 participants had been ran-
domised for more than one month. Of these, 285 (90%) had
returned a correctly completed ﬁrst Participant Diary (sent at the
time of randomisation) within one month. At the end of October
2008, 245 patients had been randomised more than 3 months.
Of these, 211 (86%) had returned the second Participant Diary.
Similarly, the return rate of the third and fourth Participant Diaries
was 156/184 (85%) and 92/112 (82%), respectively. Participants
dropping out of the study are included in the denominator of these
calculations.
Conclusions: A long development process and regular highlight-
ing/reinforcement of the importance of diary return during routine
telephone calls resulted in very high completion and return rates,
thereby demonstrating acceptability of this tool.This Participant
Diary is able to regularly capture, at low cost, important clinical
and health economic outcomes during the course of a long-term
clinical trial among people with symptomatic knee OA.
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MAGNETIC RESONANCE IMAGING: AN OPEN-LABEL PILOT
STUDY EVALUATING THE DISEASE MODIFYING EFFECT OF
CELECOXIB COMPARED TO A MODELIZED HISTORICAL
CONTROL COHORT IN KNEE OSTEOARTHRITIS
J.-P. Raynauld1, J. Martel-Pelletier1, A. Beaulieu2, L. Bessette3,
F. Morin4, D. Choquette1, B. Haraoui1, F. Abram5, J.-P. Pelletier1
1Osteoarthritis Res. Unit, Notre-Dame Hosp.,Univ. of Montreal
Hosp. Res. Ctr. (CRCHUM), Montreal, QC, Canada; 2Faculty of
Med., Univ. of Laval, Quebec, QC, Canada; 3Groupe de recherche
en rhumatologie et maladies osseuses, Sainte-Foy, QC, Canada;
4Ctr. de recherche musculosquelettique, Trois-Rivières, QC,
Canada; 5ArthroVision Inc., Montreal, QC, Canada
Purpose: An open-label 12-month pilot study evaluating the dis-
ease modifying effect of continuous treatment with celecoxib 200
mg daily compared to a modelized historical control cohort in the
treatment of knee osteoarthritis (OA).
Methods: The primary objective of this study was to evaluate, us-
ing magnetic resonance imaging (MRI), cartilage volume changes
in the medial compartment of the knee (femoral condyle and tibial
plateau) on subjects treated with celecoxib at 200 mg daily (99
patients were recruited; 78 completed the study) for 12 months
compared to a modelized historical control cohort (n=89), as ex-
pressed by percentage loss from baseline. Secondary outcomes
included other cartilage volume assessments including global and
lateral compartments as well as knee OA symptoms such as pain,
stiffness, and function, as assessed by the WOMAC questionnaire.
Safety of the medication was also assessed. The comparison be-
tween the two cohorts was evaluated by a multivariate linear
regression model.
Results: Cartilage volume loss was not reduced by celecoxib
when compared to a modelized historical cohort. Celecoxib pro-
vided clinically and statistically signiﬁcant improvement in symp-
toms for knee OA patients as shown by the WOMAC scores on
pain, stiffness and function. The safety data reported several minor
adverse events no different from those typically seen in a one-year
clinical trial.
Conclusions: Although celecoxib was demonstrated to be safe
and effective for knee OA symptom relief at a daily dose of
200 mg, it did not demonstrate a structural protective effect on
knee cartilage. Cohort modelization is an efﬁcient and unbiased
way to provide a comparator group for the assessment of novel
treatments when classic head-to-head randomized controlled trial
is not feasible.
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SHOCKWAVE PROMOTES OSTEOGENESIS OF BONE
MARROW STROMAL CELLS IN HIP NECROSIS
C.-J. Wang
Chang Gung Mem. Hosp. at Kaohsiung, Taiwan, Kaohsiung
Hsien, Taiwan
Purpose: Bone marrow stromal cells may play an important role
in hip necrosis. This in vitro study investigated the osteogenesis
effect of extracorporeal shockwave on bone marrow stromal cells
in hip necrosis.
Methods: Bone marrow stromal cells were harvested from bone
marrow cavity of six patients with hip necrosis. The specimens
were divided into four groups including the control, shockwave,
shockwave plus L-NAME and shockwave plus NOC18. The con-
trol group received no additional treatment. The shockwave group
received 500 impulses of shockwave at 14 Kv (equivalent to
0.18 mJ/mm2). The shockwave plus L-NAME group was pre-
treated with an inhibitor, L-NAME before shockwave treatment.
The shockwave plus NOC18 group consisted of the administration
of a promoter, NOC18 and application of shockwave. The evalu-
ation parameters included assessment of cell proliferation (MTT),
measurement of alkaline phosphatase level, analysis of VEGF,
BMP2, RUNX2 and osteocalcin on real time PCR and von Kossa
stain for mineralized nodules.
Results: Signiﬁcant increases of MTT, alkaline phosphatase,
VEGF, BMP2, RUNX2 and osteocalcin and more mature mineral-
ized nodules (Fig. 1) were observed after shockwave treatment as
compared to the control. Pre-treatment with L-NAME signiﬁcantly
The Results of MTT (Cell Proliferation), Alkaline Phosphatase Levels (mMol/ml),
VEGF, BMP-2, RUNX-2
Control Shockwave SW+L NAME NOC18
MTT 0.311±0.005 0.352±0.006 0.325±0.006 0.348±0.003 P1: <0.0001
(48 hrs) P2: 0.0566
P3: 0.0002
P4: 0.0496
Alkaline Phosphatase
Levels (mMol/ml)
(72 hrs) 1.537±0.152 2.442±0.156 1.996±0.138 2.438±0.042 P1: 0.001
P2: 0.0867
P3: 0.0065
P4: 0.003
VEGF 1 4.9±0.38 2.26±0.64 4.528±0.12 P1: 0.0154
P2: 0.0945
P3: 0.0252
P4: 0.0006
BMP2 1 1.57±0.18 0.83±0.12 1.46±0.09 P1: 0.0424
P2: 0.1499
P3: 0.0161
P4: 0.0016
RUNX2 1 1.6±0.17 0.93±0.03 1.97±0.19 P1: 0.0371
P2: 0.0918
P3: 0.0283
P4: 0.0065
OCN 1 2.03±0.3 0.93±0.03 2.73±0.29 P1: 0.0366
P2: 0.0918
P3: 0.0319
P4: 0.0134
